Nanonization of Megestrol Acetate by Liquid Precipitation

被引:45
|
作者
Zhang, Zhi-Bing [1 ]
Shen, Zhi-Gang [1 ]
Wang, Jie-Xin [1 ]
Zhao, Hong [1 ]
Chen, Jian-Feng [2 ]
Yun, Jimmy [3 ]
机构
[1] Beijing Univ Chem Technol, Sin China Nano Technol Ctr, Key Lab Nanomat, Minist Educ, Beijing 100029, Peoples R China
[2] Beijing Univ Chem Technol, Res Ctr, Minist Educ High Grav Engn & Technol, Beijing 100029, Peoples R China
[3] Nanomat Technol Pte Ltd, Singapore 139959, Singapore
基金
中国国家自然科学基金;
关键词
WATER-SOLUBLE DRUGS; ANTISOLVENT PRECIPITATION; NANOPARTICLES; NANOSUSPENSIONS; FORMULATION; DISSOLUTION; THERAPY;
D O I
10.1021/ie900944y
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
The purpose of this study was to prepare megestrol acetate (MA) nanoparticles via a liquid precipitation technique. Several experimental parameters, such as the stabilizer combination, the volume ratio of antisolvent to drug solution, the temperature, the stirring speed, and the drying method were investigated. The as-prepared MA particles had a mean size of 208 nm, and 90% of the particles were distributed in the range of 100-300 nm, whereas the raw MA had a mean particle size of about 3.02 mu m, ranging widely from 0.2 mu m to 30,mu m. X-ray diffraction (XRD), differential scanning calorimetry (DSC), and Fourier transform infrared (FTIR) analysis indicated that MA nanoparticles exhibited decreased crystallinity and unchanged chemical group structure after precipitation. The freeze-dried MA nanoparticles exhibited improved wettability as demonstrated by the contact angle measurement result proving that particles were covered by a hydrophilic layer. In dissolution rate tests, the nanoparticles achieved 100% drug dissolution within 5 min, while the raw MA did not dissolve completely after 120 min, suggesting that the dissolution property of MA nanoparticles was significantly enhanced.
引用
收藏
页码:8493 / 8499
页数:7
相关论文
共 50 条
  • [41] Treatment of uremic anorexia with megestrol acetate
    Fernandez Lucas, M.
    Teruel, J. L.
    Burguera, V.
    Sosa, H.
    Rivera, M.
    Rodriguez Palomares, J. R.
    Marcen, R.
    Quereda, C.
    NEFROLOGIA, 2010, 30 (06): : 646 - 652
  • [42] Induction of adrenal suppression by megestrol acetate
    Stoffer, SS
    Krakauer, JC
    ANNALS OF INTERNAL MEDICINE, 1996, 124 (06) : 613 - 614
  • [43] Megestrol acetate for geriatric anorexia/cachexia
    Haren, MT
    Kim, MJ
    Kevorkian, RT
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (01) : 172 - 173
  • [44] MEGESTROL-ACETATE IN CANCER CACHEXIA
    SCHMOLL, E
    WILKE, H
    THOLE, R
    PREUSSER, P
    WILDFANG, I
    SCHMOLL, HJ
    SEMINARS IN ONCOLOGY, 1991, 18 (01) : 32 - 34
  • [45] USE OF MEGESTROL-ACETATE IN CATS
    ROMATOWSKI, J
    JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 1989, 194 (05) : 700 - 702
  • [46] Augmentation of vincristine cytotoxicity by megestrol acetate
    Tansan, S
    Koc, Y
    Aydin, H
    Urbano, G
    McCaffrey, R
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (04) : 333 - 340
  • [47] Osteoporosis associated with megestrol acetate.
    Wermers, RA
    Hurley, DL
    Kearns, AE
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S304 - S304
  • [48] Megestrol acetate induced adrenal deficiency
    Mayaudon, H
    Eulry, F
    Dupuy, O
    Prévost, G
    Perrier, E
    Margaillan, P
    Bauduceau, B
    PRESSE MEDICALE, 1998, 27 (06): : 262 - 262
  • [49] Intracranial Hypertension Induced by Megestrol Acetate Withdrawal
    Safeer, Laraib Z.
    Chilakapati, Madhuri
    Shah, Veeral S.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2019, 39 (01) : 107 - 110
  • [50] Megestrol acetate therapy and secondary adrenal suppression
    Naing, KK
    Dewar, JA
    Leese, GP
    CANCER, 1999, 86 (06) : 1044 - 1049